Vulnerable population faces significantly higher risks

A comprehensive study of over 4,000 cannabis users in Washington State has revealed that people with psychotic disorders experience significantly more adverse health outcomes from cannabis use compared to those with other mental health conditions or no mental health diagnoses. Drawing from the International Cannabis Policy Study (2020-2023), researchers found that individuals with psychotic disorders were substantially more likely to report negative health events and seek medical attention for cannabis-related problems. Notably, these adverse outcomes extended beyond just the exacerbation of their underlying mental health condition, suggesting a broader vulnerability to cannabis effects.

The specific health risks documented among this population paint a concerning picture. People with psychotic disorders showed higher rates of Cannabis Hyperemesis Syndrome (severe cyclical vomiting), cardiovascular issues including heart and blood pressure problems, fainting episodes, acute psychosis or hallucinations, flashbacks, and nausea/vomiting. They also screened positive for high-risk cannabis use patterns at elevated rates compared to other groups. These findings were statistically significant across all measured outcomes (p < .001), demonstrating a clear and consistent pattern of increased vulnerability.

The research underscores an urgent need for targeted clinical interventions and public health campaigns specifically designed for people with psychotic disorders who use cannabis. The findings suggest that standard harm reduction messages may be insufficient for this vulnerable population, who face compounded risks from cannabis consumption. Healthcare providers working with patients who have psychotic disorders should prioritize discussions about cannabis use and its potential health impacts, going beyond traditional concerns about symptom exacerbation to address the full spectrum of physical and mental health risks.